Resonance Health Limited Overview
Resonance Health is a Perth-based micro-cap healthcare technology and clinical-services group. It has evolved from a single-product imaging-analysis company into an integrated, clinical-trial-centric platform. Its origin and reputational anchor is FerriScan, an MRI-based liver iron concentration (LIC) measurement cleared by the FDA, CE and TGA since 2005 and widely regarded as the reference standard in its niche. Around this core it has built a portfolio of regulated software-as-a-medical-device (SaMD) products covering liver iron, liver fat, cardiac iron and body composition, plus MRI elastography central reads.
Since FY24 the company has added a contract research organisation (Resonance Clinical) and a three-site investigator network in Western Australia (TrialsWest). Management describes these as three mutually referring businesses. In FY26 the group earned A$15.8M revenue (+42%) and returned to statutory profit (A$1.5M NPAT). Clinical-trial customers generated nearly 80% of revenue. A non-invasive MRI liver-fibrosis device in extended proof-of-concept is the main long-dated option.
Company's own description (FY26 Annual Report, paraphrased)
The FY26 Directors' Report describes the following:
-
The group was founded on developing and commercialising SaMD technologies and services for quantitative analysis of radiological images, delivered in a regulated, quality-controlled environment.
-
The core SaMD product is FerriScan®, a non-invasive liver iron assessment.
-
Other SaMDs include CardiacT2* (heart iron) and HepaFatScan® (liver fat), plus the AI-assisted devices FerriSmart®, HepaFatSmart® and LiverSmart®.
-
The group acts as CRO and local Australian sponsor on a clinical trial for a major global pharmaceutical company's new drug compound.
-
It operates a site management organisation trading as TrialsWest, with three trial sites in and around Perth.
The company holds ISO 13485 certification and regulatory clearances in the USA, Europe, UK and Australia. It reports three business focus areas:
-
Clinical Trial Management (CRO) Services (Resonance Clinical)
-
Clinical Trial Site Services (TrialsWest)
-
Software-as-a-Medical-Device image analysis services (SaMD, also branded "Resonance Imaging")
Business and revenue model
RHT is a services business. Its intellectual property is delivered as a regulated analysis service, not as licensed software sold per seat.
SaMD / central imaging. Customers acquire MRI scans on their own scanners using RHT protocols and upload images. RHT analysts, increasingly assisted by AI, return a regulated quantitative report.
-
Revenue is recognised per completed analysis (point in time). Clinical-trial customers also pay multi-year contract fees covering trial establishment, data management and analysis.
-
The company describes this as a "Software as a Service" model (Nov 2019 investor presentation). In accounting terms it is fee-for-service.
-
A "voucher revenue" category appears in the revenue-recognition policy, but no amounts are disclosed separately.
Resonance Clinical (CRO / local sponsor). RHT contracts directly with pharmaceutical sponsors, so far Sun Pharmaceutical Industries, to act as Australian local sponsor and CRO. It manages sites, vendors, patient payments and data, and bundles in imaging reads.
-
Revenue is recognised over time on a cost-to-complete (input) basis.
-
This gives the segment large gross revenue but includes substantial pass-through costs (site and vendor payments).
TrialsWest (site management organisation). Investigator sites in Spearwood, Osborne Park and Mandurah recruit and treat trial participants for sponsors, including GSK, Pfizer, Novartis, Sanofi and MSD (FY26 CEO letter). It is paid per patient visit and procedure under sponsor clinical trial agreements.
Revenue mix by contract type (FY26 AR Note 5):
-
Over-time clinical-trial revenue: A$9.37M (59%)
-
Point-in-time commercial (diagnostic) revenue: A$3.22M (20%)
-
Point-in-time clinical-trial revenue: A$2.40M (15%)
-
Other studies: A$0.76M (5%)
No subscription or licensing revenue is disclosed. Effectively 100% of revenue is service revenue.
Customer types and end-markets
| Customer type | Description | Evidence |
|---|---|---|
| Pharma and biotech sponsors (clinical trials) | Imaging endpoints in iron-overload (thalassaemia, sickle cell, MDS), metabolic (MASLD/MASH, obesity / GLP-1) and other trials; CRO and site services | Clinical-trial customers were nearly 80% of FY26 revenue (FY26 AR) |
| Hospitals, haematology clinics, radiology / MRI centres (diagnostics) | FerriScan / FerriSmart / HepaFat reports for patient management in chronic iron overload and fatty liver disease | Diagnostic customers were under 20% of FY26 revenue; products used in over 244 hospitals and MRI centres in FY26 (FY26 AR) |
| Single largest customer | Major global pharma under the CRO agreements (Sun Pharmaceutical Industries per contemporaneous press coverage) | 48% of FY26 revenue (FY25: 38%; FY24: 45%) (FY26 / FY25 AR Note 4) |
Value-chain position
RHT sits in the drug-development services value chain. It provides:
-
Imaging core-lab services, between the scanner (hardware OEMs) and the sponsor's endpoint analysis
-
Investigator-site services, at patient recruitment and treatment
-
CRO / local sponsorship, covering Australian trial conduct and regulatory sponsorship
In diagnostics it is a specialised quantitative post-processing provider sitting downstream of radiology practices. In the US it is reimbursed through private insurer codes, and in the UK, Germany and Canada through public systems (Stockhead, historical).
Independent characterisation
Analytically, RHT has three businesses with distinct economics.
-
A high-margin niche imaging core lab. FY26 SaMD segment pre-tax profit margin was 46.6% on A$7.0M of segment revenue. It has deep scientific credibility in liver iron and a growing presence in metabolic imaging endpoints.
-
A lumpy, single-customer-dependent CRO. Resonance Clinical earned A$7.5M revenue at a 13.4% segment margin in FY26, nearly all from one sponsor's MASH trial.
-
A small but profitable investigator-site network. TrialsWest earned A$4.1M revenue at a 24.4% segment margin in FY26.
The investment case rests on two things. First, whether the "won once, earned three times" cross-referral flywheel produces repeatable CRO wins beyond Sun Pharma. Second, whether the SaMD core lab can scale volume through automation (the Resonance Bridge and AI tooling) without proportional headcount. The liver-fibrosis device is a free option that is not in guidance.
Strategy
Stated strategy themes (FY26 AR Chair and CEO letters, FY26 results; paraphrased)
Integrated three-business platform. Management presents Resonance Imaging (SaMD), Resonance Clinical (CRO) and TrialsWest (sites) as one integrated platform. A single sponsor contract can feed all three units; the CEO describes a contract as being "won once and earned three times" (FY26 CEO letter).
Structural tailwinds. The strategy is aligned to three forces: rising liver-disease prevalence, newly approved MASH therapies that need imaging, and the growth of GLP-1 and obesity trials.
Self-funded growth. The board treats funding growth from operations as the key test of the model. The liver-fibrosis device is developed from operating cash flow, and no fibrosis revenue is assumed in near-term plans.
FY27 priorities:
-
Convert the SaMD pipeline (over A$12M of orders and bids, nearer A$13M per the FY26 webinar) and CRO opportunities into contracts.
-
Deliver the fibrosis EPoC readout and progress toward investigational use.
-
Let automation investments lift margins.
-
Pursue site-network or geographic expansion selectively.
Initiatives in the last 24 months (Oct 2024 to Oct 2026)
| Initiative | Date | Detail | Status |
|---|---|---|---|
| A$13.775M Sun Pharma CRO / sponsor contract (MASH) | Nov 2024 | Largest contract in company history; bundles CRO, site (TrialsWest) and imaging | Fully recruited (60 patients) Apr 2026; invoicing into FY27; budget reset Jun 2026 |
| TrialsWest network expansion | Aug 2024 to Jul 2025 | Osborne Park and Mandurah sites triple capacity | Osborne Park profitable; Mandurah near breakeven |
| Cost efficiency programme | Announced Aug 2025 | About A$1.1M annualised savings | Employee cost / revenue fell from 51% to 41% in FY26 |
| Exit of ASO molecular medicine; Bentley lab closure | FY25 | Refocus on nearer-term commercialisation | Complete |
| Resonance Bridge (PACS integration and automation) | Commercial testing FY25; validated 1H FY26 | Targets 5–10x analysis capacity | Customer pilots continuing into FY27 |
| AI automation of FerriScan / FerriSmart ML refinement | Ongoing | 5–10x scan-volume capability indicated by initial testing | In development |
| New imaging endpoints: MRE central read, VAT/SAT | FY25 to FY26 | Obesity and MASH trial endpoints | Material contributors to FY26 growth |
| MRI Liver Fibrosis EPoC | Multi-year; enrolment completed 1H FY26 | Readout expected early FY27; regulatory plan in preparation | Analysis underway |
| India business development | 1H FY26 | Dedicated BD manager appointed | Early stage |
| China healthcare-provider discussions | 1H FY26 | Provision of RHT services in China | Discussions only |
| Investor communications (InvestorHub, webinars, Strategy Day) | FY25 to FY26 | Strategy Day 13 Oct 2025; fibrosis webinar 9 Jun 2026 | Ongoing |
| Board renewal | Nov 2025 to Apr 2026 | New Chair; two independent NEDs with pharma and capital-markets skills | Complete |
| Reimbursement push for commercial diagnostics | Stated FY26 | Address flat diagnostic revenue | Not quantified |
Medium-term targets
| Target | Detail | Source |
|---|---|---|
| FY27 guidance | Revenue A$17–22M (+8% to +39%); normalised EBITDA A$2.6–3.6M | FY26 results |
| Medium-term objective | Scale revenue toward A$30M at an underlying EBITDA margin of about 25% | FY26 results; May 2026 upgrade |
| "Project 50:28" | Aspiration to grow from about A$16M to A$50M revenue by end of FY28, with each dollar tied to a named driver | FY26 CEO letter |
| Leverage policy | Net debt / EBITDA not to exceed 2x | FY26 earnings call (Investing.com) |
| Fibrosis device | Investigational use in pharma trials from FY27/28; commercial clearance thereafter | FY26 AR; Jun 2026 webinar |
FY27 guidance assumptions:
-
No new TrialsWest sites
-
One new CRO contract win
-
No acquisitions or geographic expansion
-
No fibrosis revenue
-
Existing trials run to full duration
ESG and sustainability commitments
None publicly disclosed.
Products & Services
SaMD segment (Resonance Imaging)
| Product | Description and capabilities | Regulatory status | Target customer | Launch / latest version | Pricing |
|---|---|---|---|---|---|
| FerriScan® | Core-lab MRI R2-based measurement of liver iron concentration (LIC). Produces mean LIC plus a colour-coded iron distribution map from about a 10-minute scan. Analysed by RHT staff in Perth, with results in about two business days. Described as the international gold standard for LIC. Over 70,000 patient analyses since launch (FY23 CEO letter). 3T compatibility added Aug 2022. A shortened protocol targeting about 75% less scan time is in validation | FDA, CE, TGA (2005); Health Canada; FDA companion diagnostic for Exjade in NTDT (2013) | Haematologists managing thalassaemia, sickle cell, MDS and haemochromatosis; trial sponsors developing chelators and iron-related drugs | 2005; 3T version 2022 | Per-analysis fee; not publicly disclosed. Reimbursed in UK, Germany and Canada, with US private-insurer codes (Stockhead, historical) |
| FerriSmart® | AI / machine-learning automated LIC from MRI, calibrated against FerriScan. Returns results within seconds and works across most scanner makes and models. Deployed via RHT's web portal and channel partners. Ongoing ML refinement aims to raise FerriScan analysis productivity 5–10x | TGA, CE (Jul 2018); FDA 510(k) (FY19) | Radiology departments wanting real-time LIC; high-volume markets | 2018–2019 | — |
| HepaFatScan® (HepaFat-Scan) | MRI liver-fat assessment. Reporting was upgraded in FY24 to a multi-metric report with PDFF (proton density fat fraction), VLFF (volumetric liver fat fraction), steatosis grade and fat distribution map | TGA, CE, FDA (FDA clearance referenced in FY2012 AR) | Hepatologists; MASLD/MASH and obesity trial sponsors | c. 2012; enhanced FY24 | — |
| HepaFatSmart® (formerly HepaFat-AI®) | AI-trained automated real-time liver-fat assessment providing VLFF, PDFF and steatosis grade | HepaFat-AI FDA Dec 2020; HepaFatSmart FDA FY23 | As above | FY23 | — |
| LiverSmart® | AI multi-parametric device combining FerriSmart and HepaFatSmart into one consolidated LIC plus liver-fat report | Regulatory-cleared per FY26 AR (jurisdictions not itemised) | Hepatology and haematology | — | — |
| CardiacT2* | MRI T2* cardiac iron assessment; offered as a dual analysis with FerriScan. A 3T version is technically complete and available in trials; regulatory submission planned (FY24 AR) | TGA, CE | Haematology; iron-overload trials | Not publicly disclosed; 3T version FY24 | — |
| MRE central read (Magnetic Resonance Elastography) | Central-read service for MRE liver-stiffness endpoints in clinical trials | Service (no separate device clearance disclosed) | MASH and obesity trial sponsors | Commenced FY25; scaled FY26 | Contract-based |
| VAT & SAT quantification | Visceral and subcutaneous adipose tissue volume quantification for body-composition endpoints | Service | GLP-1 / obesity trial sponsors | First customer FY25; material revenue in FY26 | Contract-based |
| Resonance Bridge | In-house technology integrating RHT systems with customers' PACS. Removes personal health information from images and reports, automates workflow, and targets 5–10x analysis capacity | Workflow technology | Imaging-site customers | Commercial testing FY25; validated 1H FY26; first deployments FY26–FY27 | — |
| MRI Liver Fibrosis device (development) | Multi-parametric MRI on standard hardware; 15-minute non-contrast scan; designed to neutralise iron, fat and inflammation confounders. EPoC fully enrolled with all MRI and biopsy data received; analysis underway. A secondary source reports 68 patients and an F0 vs F1+ signal (StockWireX; Jun 2026 presentation coverage) | Not cleared. Targets investigational use in pharma trials from FY27/28, then commercial clearance | MASH and fibrosis trial sponsors; hepatology | Development | Not applicable |
Resonance Clinical segment
| Service | Description | Flagship engagement |
|---|---|---|
| Australian local sponsor | Acts as the Australian regulatory sponsor for foreign pharma trials | Sun Pharma trials (2023, 2024) |
| CRO / trial management | Site selection and payments, vendor management, project and data management, trial establishment | A$6.33M contract (Aug 2023; final clinical study report issued 1H FY26). A$13.775M MASH contract (Nov 2024; 60 patients recruited Apr 2026; invoicing into FY27) |
| Bundled imaging | Central imaging reads at protocol timepoints, delivered by the SaMD segment | Included in the A$13.8M contract |
Cumulative major-pharma CRO contract wins since August 2023 total A$20.1M (FY26 results).
TrialsWest segment
| Site | Status | Performance |
|---|---|---|
| Spearwood WA (original site; 6 Barrington Street per CB Insights) | Operating since 2012 | Performing at pre-acquisition levels (FY26 AR) |
| Osborne Park WA | Announced Aug 2024 | Consistently profitable; annualised revenue run-rate above A$2M; A$1.6M FY26 revenue |
| Mandurah WA | Opened Jul 2025 | Close to breakeven in year one; ahead of plan |
Therapeutic heritage is respiratory (asthma, COPD, chronic cough), vaccines and metabolic. Expansion is targeted at metabolic/endocrine and oncology. TrialsWest was running more than 25 studies at acquisition (BioXconomy, 2024) and more than 20 active trials in FY26 (FY26 CEO letter).
Discontinued
Molecular medicine / ASO (antisense oligonucleotide) programme. This programme developed cyclophilin-type-specific drug molecules for liver and neurological disease. It ceased in FY25, and the Bentley laboratory was closed and its lease surrendered in August 2025 (FY25 AR).
Financial Narrative
All figures are AUD, from audited statements in the FY23–FY26 Annual Reports.
Income statement
Notes:
-
Gross profit is not publicly disclosed; the P&L is presented by nature of expense.
-
FY22–FY23 finance costs are not separately disclosed (lease interest is embedded in other expenses), so those cells are blank.
-
FY21 revenue was A$3.779M and FY21 NPAT A$0.586M (FY25 AR five-year table).
Margins (analyst-computed)
Revenue CAGR:
-
FY22 to FY26 (4 years): 42.4%
-
FY23 to FY26: 52.9%
-
FY21 to FY26 (5 years): about 33.0%
Balance sheet (30 June)
Notes:
-
FY24 goodwill of A$7.26M was provisional. On finalisation of purchase-price accounting (FY25 AR) it was split into goodwill A$5.25M, customer contracts/relationships A$1.81M and patient database A$0.20M, with a further A$19.5k of goodwill added in FY25.
-
Accumulated losses were A$63.5M at 30 Jun 2026 (FY26 AR).
Cash flow
Notes:
-
Company-reported FCF was A$2.8M in FY26 and A$1.1M in FY25 (FY26 results announcement). The analyst figure deducts capitalised development, which the company's measure appears to exclude.
-
The FY24 buyback of 20M Acuity collateral shares was for nil consideration.
-
In FY25 the TrialsWest outflow of A$3.91M settled almost all of the A$4.0M deferred / earn-out consideration that had been carried as a current liability at 30 Jun 2024. Only A$85k of deferred consideration remains on the FY25 and FY26 balance sheets.
Ratios (analyst-computed, year-end balances)
Notes:
-
Blank cells are not meaningful: net cash combined with negative EBITDA, or finance costs not separately disclosed.
-
The company reports "underlying ROIC" of about 18% in FY26 and about 5% in FY25. That measure is pre-tax, uses normalised EBITDA less D&A, and divides by invested capital (FY26 results). It differs from the after-tax analyst figure above.
-
A cash conversion cycle is not meaningful because there is no inventory. Payables days are not computed because the cost-of-sales base is undisclosed.
Commentary on trends, inflections and drivers
Revenue: three distinct phases.
-
FY21–FY23 was stagnation at A$3.8–4.4M, essentially FerriScan diagnostic and trial reads.
-
FY24 brought a step change (+95%) as the first Sun Pharma CRO contract booked A$3.8M and TrialsWest contributed one month.
-
FY25–FY26 compounded growth (+29% then +42%) from the larger MASH contract, the full-year and then multi-site TrialsWest, and a renewed SaMD trial-imaging cycle driven by metabolic and obesity endpoints.
The quality of growth is improving at the segment level. Organic SaMD grew 33.5% in FY26. However, group revenue concentration also rose: the largest customer was 48% of FY26 revenue.
Profitability: the FY26 inflection is real but uneven within the year.
-
1H FY26 delivered A$8.0M revenue, A$1.6M normalised EBITDA (20% margin) and A$1.5M NPAT (1H FY26 results).
-
Full-year FY26 delivered A$15.75M revenue, A$2.55–2.6M normalised EBITDA and A$1.51M NPAT.
-
That implies 2H FY26 of roughly A$7.75M revenue, about A$1.0M normalised EBITDA (about 13% margin) and approximately breakeven NPAT (analyst derivation).
The second-half softening matches the June 2026 MASH budget reset disclosed in the CEO letter and argues for caution in extrapolating the 1H run-rate.
Positive margin drivers:
-
Employee costs fell from 51% to 41% of revenue.
-
Expensed R&D fell from A$0.96M to A$0.43M.
-
Marketing and travel roughly halved, from A$0.86M to A$0.42M.
The offsetting drag is consulting and professional services, which rose from A$2.85M to A$4.03M. This line likely includes CRO pass-through and vendor costs; the FY26 AR does not itemise it.
Investors should treat the FY26 "+83% EBITDA growth" headline as measured against the adjusted A$1.4M base, not the statutory base.
Tax. RHT has reported an income tax benefit every year because of R&D tax incentive refunds of A$0.41–0.83M a year. FY26 is the first year with meaningful current tax payable (A$0.43M) and a recognised deferred tax asset (A$0.12M). Pre-tax profit (A$1.10M) is the cleaner measure of earnings power.
Balance sheet.
-
The TrialsWest acquisition, about A$8M including earn-out, converted a cash-rich, debt-free balance sheet (A$6.8M cash in FY22) into a modestly geared one.
-
Cash bottomed at A$3.0M in FY25 after the earn-out was effectively paid early.
-
FY26 operating cash generation rebuilt cash to A$4.85M against A$2.53M of NAB debt.
The key near-term item is that the entire NAB facility (A$2.53M, BBSY + 2.5%, secured over all group assets) is now classified as current because it expires 31 March 2027. Working capital has therefore compressed to A$0.88M and the current ratio to 1.13x. Management states renewal will be addressed well ahead of maturity.
Cash conversion. FY26 cash receipts (A$14.28M) trailed revenue (A$15.75M). This happened because the unearned income balance unwound from A$3.20M to A$1.23M: cash collected in advance in FY25 was recognised as revenue in FY26. DSO improved sharply to 50 days. The FY25 cash flow was flattered by A$3.2M of advance billing, and the FY26 cash flow was supported by receivables collection (down A$1.05M). Underlying cash generation is therefore best judged across FY25 and FY26 combined: about A$4.1M of operating cash flow on A$26.8M of revenue.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products / services |
|---|---|---|
SaMD | Imaging analysis core lab and the former R&D segment (merged into SaMD in the FY25 AR) | FerriScan, FerriSmart, HepaFatScan, HepaFatSmart, LiverSmart, CardiacT2*, MRE central read, VAT/SAT body composition, Resonance Bridge, liver fibrosis R&D |
Resonance Clinical | CRO and Australian local-sponsor services | Sun Pharma trial management (A$6.33M contract completed; A$13.8M MASH contract in delivery) |
TrialsWest | Site management organisation, 3 clinics | Investigator site services for sponsors (GSK, Pfizer, Novartis, Sanofi, MSD) |
Corporate (unallocated) | Head office, listed-company costs, interest income, treasury | — |
Revenue by Segment
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
SaMD revenue (AUD Mn) | 4.54 | 5.27 | 7.04 |
Resonance Clinical revenue (AUD Mn) | 3.93 | 4.16 | 7.54 |
TrialsWest revenue (AUD Mn) | 0.35 | 2.66 | 4.15 |
Intersegment elimination (AUD Mn) | -0.23 | -1.01 | -2.97 |
Group revenue (AUD Mn) | 8.59 | 11.07 | 15.75 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
SaMD PBT (AUD Mn) | 2.33 | 0.72 | 3.28 |
Resonance Clinical PBT (AUD Mn) | 2.23 | 0.33 | 1.01 |
TrialsWest PBT (AUD Mn) | 0.24 | 0.60 | 1.01 |
Corporate PBT (AUD Mn) | -5.43 | -3.84 | -4.20 |
Group PBT (AUD Mn) | -0.63 | -2.20 | 1.10 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
SaMD PBT margin (%) | 51.3 | 13.6 | 46.6 |
Resonance Clinical PBT margin (%) | 56.8 | 7.9 | 13.4 |
TrialsWest PBT margin (%) | 69.4 | 22.5 | 24.4 |
SaMD YoY revenue growth (%) | — | 16.0 | 33.5 |
Resonance Clinical YoY revenue growth (%) | — | 5.8 | 81.2 |
TrialsWest YoY revenue growth (%) | — | 661.2 | 56.1 |
SaMD share of pre-elimination revenue (%) | 51.5 | 43.6 | 37.6 |
Resonance Clinical share of pre-elimination revenue (%) | 44.6 | 34.4 | 40.3 |
TrialsWest share of pre-elimination revenue (%) | 4.0 | 22.0 | 22.1 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 3.83 | 4.40 | 8.59 | 11.07 | 15.75 |
Revenue growth (%) | 1.3 | 15.1 | 95.0 | 28.9 | 42.3 |
Other income (AUD Mn) | 0.03 | 0.11 | 0.21 | 0.09 | 0.02 |
Employee benefits expense (AUD Mn) | 2.49 | 3.11 | 3.73 | 5.63 | 6.43 |
Consulting & professional services (AUD Mn) | 0.24 | 0.24 | 1.70 | 2.85 | 4.03 |
R&D expensed (AUD Mn) | 0.72 | 0.71 | 0.84 | 0.96 | 0.43 |
Share-based payments (AUD Mn) | 0.01 | 0.02 | 0.83 | 0.19 | 0.21 |
Statutory EBITDA (AUD Mn) | -1.13 | -0.86 | -0.13 | -0.99 | 2.34 |
Normalised EBITDA per AR five-year table (AUD Mn) | -1.12 | -0.84 | 0.70 | -0.72 | 2.55 |
EBIT / operating income (AUD Mn) | -1.56 | -1.30 | -0.69 | -1.96 | 1.39 |
Finance costs (AUD Mn) | — | — | 0.05 | 0.32 | 0.34 |
Profit before tax (AUD Mn) | -1.55 | -1.26 | -0.63 | -2.20 | 1.10 |
Income tax benefit (AUD Mn) | 0.41 | 0.48 | 0.80 | 0.47 | 0.41 |
Net profit after tax (AUD Mn) | -1.14 | -0.78 | 0.17 | -1.73 | 1.51 |
Basic EPS (AUD cents) | -0.25 | -0.17 | 0.04 | -0.38 | 0.32 |
Diluted EPS (AUD cents) | -0.25 | -0.17 | 0.04 | -0.38 | 0.31 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Statutory EBITDA margin (%) | -29.4 | -19.6 | -1.5 | -9.0 | 14.9 |
Normalised EBITDA margin (%) | -29.3 | -19.0 | 8.1 | -6.5 | 16.2 |
EBIT margin (%) | -40.6 | -29.5 | -8.1 | -17.7 | 8.8 |
Pre-tax margin (%) | -40.5 | -28.7 | -7.3 | -19.9 | 7.0 |
Net margin (%) | -29.8 | -17.7 | 2.0 | -15.7 | 9.6 |
Employee costs as % of revenue | 65.2 | 70.6 | 43.4 | 50.9 | 40.8 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | 11.69 | 10.98 | 20.28 | 17.89 | 18.74 |
Cash & equivalents (AUD Mn) | 6.78 | 6.36 | 6.85 | 2.98 | 4.85 |
Trade & other receivables (AUD Mn) | 1.51 | 1.14 | 2.32 | 3.52 | 2.47 |
Bank debt, current (AUD Mn) | 0 | 0 | 0.32 | 0.32 | 2.53 |
Bank debt, non-current (AUD Mn) | 0 | 0 | 2.85 | 2.53 | 0 |
Total bank debt (AUD Mn) | 0 | 0 | 3.17 | 2.85 | 2.53 |
Lease liabilities (AUD Mn) | 0.27 | 0.27 | 0.52 | 0.95 | 1.28 |
Net debt, bank only (AUD Mn) | -6.78 | -6.36 | -3.68 | -0.12 | -2.32 |
Net debt incl. leases (AUD Mn) | -6.51 | -6.09 | -3.16 | 0.83 | -1.04 |
Goodwill (AUD Mn) | 0 | 0 | 7.26 | 5.27 | 5.27 |
Total intangibles incl. goodwill (AUD Mn) | 2.87 | 2.71 | 9.86 | 9.54 | 9.25 |
Deferred consideration, TrialsWest (AUD Mn) | 0 | 0 | 4.00 | 0.09 | 0.09 |
Unearned income (AUD Mn) | 0.02 | 0.01 | 0.01 | 3.20 | 1.23 |
Total liabilities (AUD Mn) | 1.00 | 1.05 | 9.35 | 8.50 | 7.63 |
Total equity (AUD Mn) | 10.69 | 9.94 | 10.93 | 9.39 | 11.11 |
Working capital (AUD Mn) | 7.54 | 6.68 | 3.14 | 1.43 | 0.88 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Receipts from customers (AUD Mn) | 3.53 | 4.33 | 8.11 | 13.97 | 14.28 |
Net operating cash flow (AUD Mn) | -1.46 | -0.16 | 1.39 | 1.25 | 2.88 |
R&D tax incentive / income tax received (AUD Mn) | 0 | 0.89 | 0.80 | 0.21 | 0.73 |
Capex, PP&E (AUD Mn) | 0.12 | 0.29 | 0.23 | 0.44 | 0.09 |
Capitalised development / intangibles (AUD Mn) | 0.58 | 0.18 | 0.15 | 0.18 | 0.21 |
Free cash flow, OCF less PP&E less intangibles (AUD Mn) | -2.16 | -0.62 | 1.01 | 0.63 | 2.58 |
Acquisition of TrialsWest, net (AUD Mn) | 0 | 0 | 3.56 | 3.91 | 0 |
Borrowings drawn (AUD Mn) | 0 | 0 | 3.20 | 0 | 0 |
Borrowings repaid (AUD Mn) | 0 | 0 | 0.03 | 0.32 | 0.32 |
Lease principal repaid (AUD Mn) | 0.07 | 0.08 | 0.13 | 0.29 | 0.31 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Cash buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%) | -10.7 | -7.9 | 1.5 | -18.5 | 13.6 |
ROA (%) | -9.8 | -7.1 | 0.8 | -9.7 | 8.1 |
ROIC, EBIT x 0.75 / (equity + bank debt − cash) (%) | -29.8 | -27.3 | -7.2 | -15.8 | 11.8 |
Current ratio (x) | 10.34 | 8.63 | 1.51 | 1.28 | 1.13 |
Bank debt / equity (x) | 0 | 0 | 0.29 | 0.30 | 0.23 |
Bank + lease debt / equity (x) | 0.03 | 0.03 | 0.34 | 0.40 | 0.34 |
Net debt / statutory EBITDA (x) | — | — | — | — | -0.99 |
Interest coverage, EBIT / finance costs (x) | — | — | -14.7 | -6.1 | 4.1 |
Asset turnover, revenue / total assets (x) | 0.33 | 0.40 | 0.42 | 0.62 | 0.84 |
Days sales outstanding, trade receivables (days) | 100 | 92 | 100 | 87 | 50 |
Largest customer share of revenue (%) | 11 | 14 | 45 | 38 | 48 |
Revenue by Region
| Region | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Asia/Pacific revenue (AUD Mn) | 0.33 | 0.29 | 4.32 | 2.75 | 10.07 |
North America revenue (AUD Mn) | 2.58 | 2.78 | 2.64 | 2.03 | 3.93 |
EMEA revenue (AUD Mn) | 0.92 | 1.33 | 1.64 | 6.30 | 1.75 |
South America revenue (AUD Mn) | 0.004 | 0 | 0 | 0 | 0 |
Total (AUD Mn) | 3.83 | 4.40 | 8.59 | 11.07 | 15.75 |
Region Margins & Growth (%) and Revenue by Region (%)
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Asia/Pacific YoY growth (%) | -10.4 | 1,369.5 | -36.4 | 266.6 |
North America YoY growth (%) | 7.9 | -5.2 | -23.1 | 93.8 |
EMEA YoY growth (%) | 44.5 | 22.9 | 285.2 | -72.2 |
Asia/Pacific share (%) | 6.7 | 50.3 | 24.8 | 63.9 |
North America share (%) | 63.1 | 30.7 | 18.3 | 24.9 |
EMEA share (%) | 30.2 | 19.0 | 56.9 | 11.1 |
Share Price
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
Share price at 30 June (AUD) | 0.16 | 0.06 | 0.04 | 0.06 | 0.04 | 0.04 |
Share Price & Returns
| Period | Return |
|---|---|
1-year (from about A$0.041 at 1 Jul 2025, the closest verified datapoint) | About +45% |
3-year (from A$0.04, Jun 2023) | About +50% |
5-year (from A$0.16, Jun 2021) | About −63% |
Valuation Multiples
| Multiple | RHT (FY26 actuals) | RHT (FY27 guidance range) |
|---|---|---|
P/E (x) | 17.8 | Not available (no EPS guidance) |
EV / statutory EBITDA (x) | 10.5 | — |
EV / normalised EBITDA (x) | 9.6 | 6.8–9.5 |
EV / sales (x) | 1.56 | 1.1–1.4 |
P/B (x) | 2.42 | — |
P / tangible book (x) | About 14 (NTA 0.12c per share) | — |
EV / FCF, company-reported A$2.8M (x) | About 8.8 | — |
Capital Instruments
| Instrument | Amount (AUD Mn) | Rate | Security | Maturity |
|---|---|---|---|---|
NAB secured finance facility | 2.53 | BBSY + 2.5% | All assets of RHT and TrialsWest | 31 Mar 2027 |
Lease liabilities | 1.28 (current 0.23; non-current 1.05) | Implicit | Leased premises | Various; five premises |
Analyst Conclusions
Management guidance (FY26 results, 28 Aug 2026)
| Metric | FY2026 actual | FY2027 guidance low | FY2027 guidance high |
|---|---|---|---|
| Revenue (AUD M) | 15.75 | 17.0 | 22.0 |
| Normalised EBITDA (AUD M) | 2.6 | 2.6 | 3.6 |
| Normalised EBITDA margin (%) | 16.2 | 15.3 | 16.4 |
Medium term: about A$30M revenue at about 25% EBITDA margin. The aspirational "Project 50:28" target is A$50M revenue by end of FY28.
Consensus: none (no coverage). The guidance range implies flat-to-modest margin progression in FY27. Revenue growth is heavily dependent on the assumed single new CRO win.
Bull case
-
Operating leverage is proven and scalable. Incremental EBITDA margin was about 25% in FY26 and employee intensity fell 10 points. If the Bridge and AI deliver even part of the claimed 5–10x analysis capacity, SaMD margins (already 46.6% at segment PBT) can rise as metabolic-trial volumes grow against an over-A$12M pipeline.
-
Structural demand tailwinds. Two approved MASH drugs, GLP-1 trial proliferation and regulatory demand for non-invasive fibrosis biomarkers align directly with RHT's endpoints. North American revenue grew 94% in FY26.
-
Cheap free option. At about 9.6x trailing normalised EBITDA, about 1.6x EV/sales, net cash and self-funding status, the fibrosis device receives roughly zero value. A positive EPoC readout in early FY27 could re-rate the stock toward MASH-imaging peers.
Bear case
-
The MASH contract cliff. The A$13.8M contract (A$7.54M, or 48%, of FY26 revenue) completes in early calendar 2027. FY27 guidance already assumes a replacement CRO win that has not been announced. The 2H FY26 slowdown to about breakeven NPAT shows how sensitive earnings are to one trial's economics.
-
Earnings quality and disclosure. Normalised EBITDA definitions shift between documents (the FY25 base of −A$0.72M vs +A$1.4M). Tax-incentive benefits inflate NPAT. Geographic reclassification is unexplained. The FY26 cash flow was supported by working-capital release (receivables down A$1.05M).
-
Scale and competitive disadvantage. At A$15.8M revenue with A$4.2M of corporate overhead, RHT is sub-scale against well-funded Perspectum and global core labs. Several patents are lapsing. Refinancing falls due in March 2027. The board lacks diversity. The stock is illiquid with no institutional sponsorship.
Key catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable |
|---|---|
| Early FY27 (late 2026) | Liver-fibrosis EPoC readout and regulatory plan |
| 19 Nov 2026 | AGM: trading update; remuneration report vote; any FY27 guidance commentary |
| FY27 | New Resonance Clinical CRO contract announcement, which guidance assumes |
| By 31 Mar 2027 | NAB facility refinancing terms |
| Feb 2027 | 1H FY27 results (expected about 26 Feb 2027 per InvestSMART calendar): run-rate vs guidance; MASH trial wind-down |
| FY27 | Conversion of the over-A$12M SaMD pipeline; Bridge deployments |
| FY27 | Customer concentration below 40% |
| FY27 | Any TrialsWest site acquisitions; India and China contract wins |
| May 2027 | Expiry of TrialsWest founders' three-year retention commitment |
Analyst verdict
Resonance Health has completed a difficult transition. In FY23 it was a stagnant, loss-making single-product imaging company with A$4.4M of revenue. In FY26 it is a cash-generative, profitable three-business platform with A$15.8M of revenue, positive operating cash flow in every quarter and net cash. The strategic logic is sound: a niche, high-margin imaging core lab with genuine reference-standard credibility, attached to Australian CRO and investigator-site capabilities that keep more of each sponsor dollar in the group. Intersegment eliminations of A$3.0M show the cross-referral flywheel working, and the SaMD segment's 46.6% FY26 margin confirms the core remains valuable.
The dossier nonetheless argues for discipline in extrapolation. FY26 profit was front-loaded: roughly A$1.5M NPAT in 1H against breakeven in 2H. Nearly half of revenue came from one Sun Pharma MASH trial that ends in early 2027, after a margin-reducing budget reset. FY27 guidance of A$17–22M revenue and A$2.6–3.6M normalised EBITDA implies little margin expansion and relies on an unannounced CRO win. The NAB facility must be refinanced by March 2027. Disclosure is adequate but uneven, including inconsistent normalised EBITDA and unexplained regional swings.
At about A$27M market capitalisation (about 1.6x EV/sales and under 10x trailing normalised EBITDA), the market appears to price RHT as a small services company with concentration risk. It assigns little value to the automation upside or the fibrosis device. That framing seems broadly fair today. The equity's asymmetry depends on two near-term binary events: a credible replacement CRO contract, and a positive fibrosis EPoC readout.
Verdict: a speculative but improving micro-cap. Fundamental momentum is positive and insider alignment is strong, but customer concentration and execution risk are high. The thesis should be re-underwritten after the EPoC readout and the next CRO contract announcement.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / education | Age |
|---|---|---|---|---|
Andrew Harrison | Managing Director & CEO | CEO since 1 Jul 2023; MD since 1 Oct 2025 | Founder and MD/CEO of Capitol Health Ltd (ASX: CAJ), MD/CEO Nov 2016 to Jun 2019; former director of Enlitic LLC (US medical AI); M&A, capital markets and turnaround experience; BComm (Hons) | 54 (Simply Wall St, 2025) |
Benjamin Carruthers | Chief Financial Officer | Since 9 Oct 2023 | Former GM of SFM Marine; former Executive Director at KordaMentha; 20+ years in advisory, restructuring and turnaround | — |
Mitchell Wells | Company Secretary (part-time consultant) and NED | Director since 28 Feb 2018; MD 1 Jul 2021 to 1 Jul 2023 | Lawyer with Australian, US and UK experience; former company secretary of ASX- and Nasdaq-listed companies; LLB, BComm, Dip. Aviation (CPL) | — |
Dr Helen Pavitt | VP, Clinical Trials (TrialsWest founder) | Since acquisition (May 2024) | Co-founder of TrialsWest | — |
Michelle Davies; Prof. Peter Bremner | TrialsWest co-founders, key leadership roles | Since acquisition | Committed to remain at least three years post-completion | — |
“—” = not publicly disclosed.
Board of Directors
| Director | Role | Independent | Appointed | Background | Committees | Shareholding |
|---|---|---|---|---|---|---|
Aaron Brinkworth | Non-executive Chair (since 13 Nov 2025) | Yes | 27 Mar 2023 | 22 years at Gilead Sciences incl. Executive Director, Global Patient Solutions and APAC commercial lead; NED of Proteomics International (ASX: PIQ), Atherid Therapeutics, Lixa; BHlthSc, GAICD | Chair, Remuneration; member, Audit & Risk | 1,107,647 shares |
Andrew Harrison | MD & CEO | No | Director 1 Oct 2025 | See above | — | 8,000,000 shares plus 11,070,857 loan shares |
Mitchell Wells | NED & Company Secretary | No (former executive; paid consultant) | 28 Feb 2018 | See above | Member, Audit & Risk | 2,830,000 shares |
Simon Panton | NED | No (substantial shareholder; board since 2009) | 5 Oct 2009 | Business owner; long-term supporter and major shareholder | Audit & Risk; Remuneration | 80,137,174 shares |
Dr Travis Baroni | NED | Yes | 25 Nov 2016 | Applied physics PhD (UWA); industrial R&D; investment banking / ECM | Chair, Audit & Risk; member, Remuneration | 1,130,000 shares |
Dr David Fuller | NED | Yes | 28 Apr 2026 | Pharmaceutical physician and pharmacist with 30+ years in drug development; CMO of Dimerix (ASX: DXB); MBBS, B.Pharm (Hons) | Audit & Risk; Remuneration | 98,701 shares |
Michael Sistenich | NED | Yes | 28 Apr 2026 | CEO and director of Enlitic Inc. (ASX: ENL), formerly its Chair; ex-CEO of Nohla Therapeutics; ex-NED of Opthea; MSc BioChem | Audit & Risk; Remuneration | Nil |
Directors' Remuneration
| Name | Cash salary / fees | STI / bonus | Non-monetary | Superannuation | Equity-settled | Total |
|---|---|---|---|---|---|---|
A Harrison (MD & CEO) | 433,773 | 125,520 | 9,900 | 30,000 | 44,004 | 643,197 |
B Carruthers (CFO) | 314,781 | 54,520 | 5,313 | 30,000 | 29,374 | 433,988 |
M Wells (NED / Co Sec / consultant) | 232,625 | 0 | 0 | 0 | 3,426 | 236,051 |
A Brinkworth (Chair) | 78,089 | 0 | 0 | 9,371 | 0 | 87,460 |
S Panton | 58,296 | 0 | 0 | 6,996 | 0 | 65,292 |
T Baroni | 58,296 | 0 | 0 | 6,996 | 0 | 65,292 |
M Blake (to 13 Nov 2025) | 33,134 | 0 | 0 | 3,976 | 0 | 37,110 |
D Fuller (from 28 Apr 2026) | 10,682 | 0 | 0 | 1,282 | 0 | 11,964 |
M Sistenich (from 28 Apr 2026) | 10,682 | 0 | 0 | 1,282 | 0 | 11,964 |
Total KMP | 1,230,358 | 180,040 | 15,213 | 89,903 | 76,804 | 1,592,318 |
Major Shareholders
| Holder | Shares | Approx. % of ~474.8M | Source / date |
|---|---|---|---|
Simon Panton (NED) | 80,137,174 | 16.9 | FY26 AR (27 Aug 2026) |
Andrew Harrison (incl. 11.07M loan shares) | 19,070,857 | 4.0 | FY26 AR |
Paul Van Dyk | 9,250,031 | 1.9 | Simply Wall St (2025; may be stale) |
Benjamin Carruthers (loan shares) | 7,342,553 | 1.5 | FY26 AR |
William Thompson | 6,658,660 | 1.4 | Simply Wall St (2025) |
Jade Thompson | 6,512,759 | 1.4 | Simply Wall St (2025) |
Harish Garg | 6,500,000 | 1.4 | Simply Wall St (2025) |
Dr Martin Blake (at resignation) | 6,464,677 | 1.4 | FY26 AR (Nov 2025) |
Mitchell Wells | 2,830,000 | 0.6 | FY26 AR |
Dr Travis Baroni | 1,130,000 | 0.2 | FY26 AR |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type | Positioning vs RHT | Revenue |
|---|---|---|---|---|
SaMD: liver imaging | Perspectum (UK) | Private | LiverMultiScan (cT1, fat, iron); FDA-cleared; US reimbursement; also offers CRO imaging services. The most direct liver-MRI rival in MASH. Raised about US$140M+ by 2023; 192 employees at the abandoned 2021 IPO | — |
SaMD: liver stiffness | Resoundant (US) | Private | MR Elastography technology owner; RHT now offers MRE central reads | — |
SaMD: non-imaging liver tests | Echosens (FibroScan) | Private | Ultrasound transient elastography; dominant point-of-care non-invasive test for MASH; competes with MRI-based fibrosis | — |
Imaging core lab / iCRO | Clario (incl. former Bioclinica) | Private | Global scale imaging core lab | — |
Imaging core lab / iCRO | Median Technologies (Euronext Growth: ALMDT) | Listed | Oncology iCRO plus eyonis SaMD | €23.5M CY2025 (+2.6%); backlog €76.6M |
Imaging core lab / iCRO | IXICO plc (AIM: IXI) | Listed | Neuroscience imaging biomarkers | £6.5M FY Sep-2025 (+13%); EBITDA −£1.3M |
Imaging core lab / iCRO | Calyx, Imaging Endpoints, Radiant Sage, ICON, Parexel, Medpace imaging units | Private or divisions | Full-service imaging within large CROs | — |
Scanner OEM tools | Siemens Healthineers, GE HealthCare, Philips | Listed majors | Inline R2* / PDFF / T2* mapping on scanners erodes demand for basic quantification. Analyst characterisation | Segment revenue not disclosed |
CRO (Australia) | Novotech, Avance Clinical, IQVIA, George Clinical, Southern Star Research | Private / listed | Established Australian CROs competing for local-sponsor and trial management work. Analyst characterisation | — |
Investigator sites (WA / Australia) | Linear Clinical Research (Perth), Paratus Clinical, other SMOs and hospital trial units | Private / not-for-profit | Competition for sponsor site selection and patients. Analyst characterisation | — |
“—” = not publicly disclosed.
Peer Comparison FY2027
| Metric | Resonance Health (FY Jun-2026) | Median Technologies (CY2025) | IXICO (FY Sep-2025) | Pro Medicus (FY Jun-2026, adjacent imaging software) |
|---|---|---|---|---|
Revenue | A$15.75M | €23.5M | £6.5M | A$261.7M |
Revenue growth | +42.3% | +2.6% | +13% | +22.9% |
EBITDA margin | 14.9% statutory; 16.2% normalised | — | about −20% (EBITDA −£1.3M) | EBIT margin 74.9% |
Net margin | 9.6% | — | Loss | Underlying NPAT A$144.7M (55%) |
R&D intensity | 2.8% expensed; 4.1% incl. capitalised | — | — | — |
Recent Developments
Items with nothing to report in the period: * litigation, regulatory enforcement and layoffs.



